The vaccine would be given to pregnant mothers and protect their babies starting at birth.
Initial trail results for the vaccine showed very promising results.Now that COVID-19 restrictions are lifted in most places and life is somewhat “back to normal,” we’re all back to being at risk for getting some sort of sickness, COVID or otherwise, especially with school back in session. Currently, hospitals across the country areOne of the worst illnesses that is spreading like wildfire has been, a respiratory virus that can be especially harsh and even dangerous in babies and young children.
It may seem like your kid is sick every other week from something, or maybe you’re worried about RSV and how it could affect your child if they become infected. There could be some hope on the horizon to help ease that stress. Pfizer says it has enough promising data on its RSV vaccine that it will end enrollment in the study currently going on and submit approval from the FDA approval by the end of the year. Pfizer’s vaccine candidate would be administered to pregnant women who then make antibodies that cross the placenta and protect the baby after birth.
“The [study data monitoring committee] recommended, based on the data that we have, that we should go ahead and file, that this offers the potential for a safe and effective vaccine that could really dramatically help to prevent RSV during the winter season,” Dr.
According to CNN, Pfizer’s vaccine contains the F-protein found in RSV, which the virus uses to attach to human cells. The protein is frozen into the shape it folds into before it fuses with a cell, so the immune system can build antibodies against it. Pfizer’s RSV vaccine is bivalent, containing F-proteins from both the A and B subgroups of the RSV virus, which are the two most commonly circulating strains.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer Squares Off With Merck, Other Drugmakers Over Lucrative Pneumonia VaccinesThe growing $7 billion market is currently dominated by Pfizer, and rivals’ interest in winning more of the business shows the pharmaceutical industry’s renewed focus on vaccines.
Read more »
Pfizer RSV vaccine given to pregnant mothers is effective at protecting newborns, company's data showsPfizer said it will submit an application to the Food and Drug Administration for the RSV vaccine's approval by the end of 2022.
Read more »
Pfizer says study shows vaccinating pregnant women protects newborns from RSVThe preliminary results buoy hope that after decades of failure and frustration, vaccines against RSV may finally be getting close.
Read more »
RSV Vaccine Protected Infants From Severe Cases, Pfizer Study FindsAn RSV vaccine given to pregnant women significantly reduced the risk of severe cases in their infants. The study comes as doctors report unusually high numbers of the respiratory illness.
Read more »
Pfizer stock climbs on Q3 top and bottom line beat, raised outlookPfizer Inc.'s undefined stock rose 3.4% before market open on Tuesday, lifted by the pharmaceutical giant's third-quarter earnings. The company earned $1.51...
Read more »